Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.

Détails

Ressource 1Télécharger: BIB_A5C4E2B35318.P001.pdf (589.91 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_A5C4E2B35318
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.
Périodique
Plos One
Auteur(s)
Carmeli C., Knyazeva M.G., Cuénod M., Do K.Q.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
7
Numéro
2
Pages
e29341
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Résumé
Glutathione (GSH) dysregulation at the gene, protein, and functional levels has been observed in schizophrenia patients. Together with disease-like anomalies in GSH deficit experimental models, it suggests that such redox dysregulation can play a critical role in altering neural connectivity and synchronization, and thus possibly causing schizophrenia symptoms. To determine whether increased GSH levels would modulate EEG synchronization, N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients in a randomized, double-blind, crossover protocol for 60 days, followed by placebo for another 60 days (or vice versa). We analyzed whole-head topography of the multivariate phase synchronization (MPS) for 128-channel resting-state EEGs that were recorded at the onset, at the point of crossover, and at the end of the protocol. In this proof of concept study, the treatment with NAC significantly increased MPS compared to placebo over the left parieto-temporal, the right temporal, and the bilateral prefrontal regions. These changes were robust both at the group and at the individual level. Although MPS increase was observed in the absence of clinical improvement at a group level, it correlated with individual change estimated by Liddle's disorganization scale. Therefore, significant changes in EEG synchronization induced by NAC administration may precede clinically detectable improvement, highlighting its possible utility as a biomarker of treatment efficacy. TRIAL REGISTRATION: ClinicalTrials.gov NCT01506765.
Mots-clé
Acetylcysteine/pharmacology, Adult, Biological Markers, Cross-Over Studies, Double-Blind Method, Electroencephalography/methods, Female, Free Radical Scavengers/pharmacology, Glutathione/metabolism, Humans, Male, Models, Statistical, Multivariate Analysis, Oscillometry, Oxidation-Reduction, Placebos, Schizophrenia/drug therapy, Schizophrenia/physiopathology, Signal Processing, Computer-Assisted
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/03/2012 15:43
Dernière modification de la notice
20/08/2019 16:10
Données d'usage